MV TELEGRAPH

Adar Poonawalla became CEO of the world’s largest vaccine manufacturer, Serum Institute of India, at the age of 30.

| Bloomberg | Getty Images

Adar Poonawalla became CEO of the world’s largest vaccine manufacturer, Serum Institute of India, at the age of 30.

But this wasn’t his first foray into the family business.

“I started, you know, at the grassroots level. I worked in all departments – and especially in marketing and sales and in export, because I wanted to build up exports,” explains the 41-year-old CEO.

The company has come a long way since its acquisition in 2011.

Today it is the world’s largest vaccine manufacturer – measured by the number of doses produced and sold worldwide. According to the company, it delivers “the world’s cheapest and WHO-approved vaccines to up to 170 countries.”

Adar ran the company at the height of the global pandemic. During this time, the Serum Institute increased its production for Covid vaccines to meet global demand and began manufacturing Covishield in India – a vaccine co-developed by AstraZeneca and the University of Oxford that is manufactured domestically.

According to the Indian Ministry of Health, Covishield accounts for almost 80% of all vaccines administered in India to date.

“We’ve invested about $2 billion over the past two years,” Adar said, adding that the completed pandemic facility “doubled our capacity.”

“We produced 1.9 billion cans in 2021 alone after committing to just 1 billion cans, so we did double what we promised.”

According to Adar, they can now produce 4 billion doses of different vaccines at the new facility.

The man behind

It was Adar’s father, Cyrus Poonawalla, who founded the Serum Institute of India in 1966 – against the backdrop of a country deluged with imported life-saving vaccines. However, the high cost of the drugs meant they were virtually inaccessible to most of India’s population.

Cyrus never imagined himself in the pharmaceutical industry – in fact he was a horse breeder who inherited his family’s racehorse breeding.

But he soon learned that horse serum was an essential ingredient in many vaccines, and that many of his farm’s retired horses were donated to the state’s Haffkine Institute for vaccine production.

At the same time Cyrus Realized vaccination rates have remained low in India, partly due to the high prices of imported vaccines.

In 1966, at the age of 25, the elder Poonawalla embarked on a journey to found the Serum Institute of India.

The company’s first product was the tetanus vaccine in 1967.

A new generation

Following in his father’s footsteps, Adar is still working on the company’s early efforts to produce vaccines at affordable prices.

“We could have asked for higher prices. But we didn’t do it,” he told CNBC Make It. “We didn’t want to take advantage beyond the point. We just wanted to make a product that is so accessible and affordable.”

By using their economies of scale to minimize costs, his company has now become the world’s largest vaccine manufacturer, with an estimated 65% of the world’s children having received a Serum Institute of India vaccine, according to the company.

Through time and experience, Adar was able to understand and predict global trends and demand, making him even more determined to ensure adequate supply. It was this forward planning that contributed to Serum’s successful and active engagement during the pandemic.

Thanks to his foresight, this decision “was also very practical during the Covid crisis” and the company had “additional capacities”.

Adar’s extensive travels also meant he met people from different places and was able to “understand where global demand was going”.

This knowledge was a driving factor that encouraged him to build enough capacity to ensure the company was able to produce enough to meet growing global demand.

Rough road ahead

However, success did not come easily.

Starting the company was a “big hurdle” for his father in the ’70s, who had to obtain permits and licenses, Adar said.

Raising enough capital to kickstart the business also proved a challenge for Cyrus, who “had no track record and no brand name,” he explained.

Vaccine production at Serum Institute of India Pharmaceutical Plant in Pune, Maharashtra, India. Like the rest of the world, the vaccine maker is currently moving away from its heavy focus on Covid-19 vaccines and expanding its product portfolio.

Bloomberg | Bloomberg | Getty Images

Shortly after joining the company, Adar was determined to increase production volumes when he realized that the company was constantly missing out on “new opportunities”.

That awareness made it “very obvious and very straightforward” for him to invest in capacity, Adar told CNBC Make It.

With the increasing urgency of Covid vaccines around the world as the pandemic spread, Adar was determined to make realistic promises to meet vaccine demand.

“You can make billions of cans if you have a year or two, but to do it in three or four months — that’s what the world really needs,” Adar stressed that meeting those expectations is crucial fulfill.

The next chapter

Like the rest of the world, Serum Institute of India is moving away from its heavy reliance on Covid-19 vaccines and is now shifting its focus to expanding its product portfolio.

As the company develops, Adar said he is looking to enter new markets.

“I am considering further expanding my portfolio of vaccines now in Europe and the United States.”

Meanwhile, the CEO said he remains hopeful that if action is taken now, the world could be better prepared for future pandemics.

“We know what we have to do,” he explained. “But do we do that is the issue I think leaders need to address.”

Adar said he remains enthusiastic about helping other low-income countries like the African continent and Asia give them affordable access to life-saving vaccinations.

“I’m honestly quite relieved that the Covid pandemic is nearing an end – because I can get back to my pipeline of vaccines that I’ve been developing over the last few years,” Adar said.

“I just want to get back to that. And I look forward.”

Don’t Miss: How Two Teens Built a $900M App – Zepto’s Founders share three tips

Like this story? Subscribe to CNBC Make It on YouTube!

The latest Omicron boosters are 84% effective at preventing seniors aged 65 and older from being hospitalized with Covid-19 compared to the unvaccinated, according to a study published Friday by the Centers for Disease Control and Prevention.

And seniors who received the Omicron booster shot had 73% more protection from hospitalizations than those who received only two or more doses of the original vaccines that weren’t updated to Omicron, according to the CDC.

The study was conducted from September to November when omicron BA.5 and the even more vulnerable variants BQ.1 and BQ.1.1 were dominant. About 800 seniors with an average age of 76 years were included in the analysis.

In a larger study involving more than 15,000 adults aged 18 and over, the omicron booster was 57% effective in preventing hospitalizations. Adults who received the booster shot had 38% additional protection compared to those who only received the original shots.

None of the studies looked at how well people were protected from hospitalization if they were vaccinated and had natural immunity to previous Covid infection.

A previous study by the CDC found that the boosters were less than 50% effective at preventing mild illness in most age groups. However, prominent scientists and public health experts said the vaccines’ effectiveness against hospitalization would almost certainly be higher.

US health officials have repeatedly called on anyone eligible to receive an Omicron booster shot before the holiday. However, the Government has been particularly focused on ensuring that more vulnerable populations such as older adults remain up to date on their Covid vaccines.

dr Ashish Jha, the head of the White House Covid task force, said most of the people currently dying from Covid are seniors who are not up to date on their vaccinations or who are not receiving treatment if they have breakthrough infections.

“There are still too many older Americans who haven’t updated their immunity, who haven’t protected themselves,” Jha told reporters at the White House on Thursday.

The Biden administration is launching a campaign to increase immunizations in nursing homes, whose residents are among those most at risk for severe Covid. Less than 50% of nursing home residents have received the updated booster shot.

Overall, according to CDC data, only 35% of seniors received an Omicron booster shot, while 14% of those 5 years and older received the updated shot.

The Centers for Disease Control and Prevention on Thursday released new child body mass index charts in response to the growing obesity crisis in the United States

The previous BMI chart for children aged 2 to 19 years published in 2000 is based on data from 1963 to 1980, but childhood obesity and severe obesity has increased significantly since the 1980s. More than 4.5 million children and adolescents suffered from severe obesity in 2018, according to the CDC.

related investment news

BMI is calculated using a mathematical formula that measures body fat, generally by dividing a person’s height by their weight. For adults, a healthy BMI is between 18.5 and 24.9, or 111 pounds. to about 150 pounds. for someone who is 5’5″. At 5’10”, a healthy BMI is between 129lbs. and 175 pounds. For adults 20 years and older, a BMI of 30 or more is considered obese.

The previous charts for children did not go beyond a BMI of 37. The new charts go up to a BMI of 60 and measure whether it is within healthy parameters based on a percentile measured against other children of the same age and sex.

“Prior to today’s release, growth charts were not high enough to represent BMI for the increasing number of children with severe obesity,” said Dr. Karen Hacker, director of the CDC’s National Center for Chronic Disease Prevention and Health Promotion.

The BMI for children up to the age of 20 runs along a sliding range depending on age and gender. Under the new guidelines, a healthy child BMI can range from about 13 to about 17 for a 6-year-old girl or boy to a range of about 18 to about 26 for a 20-year-old woman.

The expanded charts will help health care providers work with families to treat children suffering from obesity, Hacker said. The 2000 BMI charts are still used for children who are not obese, according to the CDC.

Obesity among children has increased dramatically over the past 40 years. During the four-year period to 1980, 5.5% of children aged 2 to 19 years were obese and 1.3% were severely obese. According to the National Center for Health Statistics, in 2018, 19.3% of children were obese and 6.1% were severely obese.

Childhood obesity is defined as a BMI greater than 95% of children of the same age and sex, according to the CDC. Severe obesity is a BMI that is 120% above the 95th percentile.

Although children’s BMI is calculated using the same formula as adults, a healthy weight is measured relative to other children of the same age and sex. This is because children’s height and weight can vary significantly as they get older.